Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Bugianesi

Showing results (41-50 of 326) with videos related to

Pageof 33
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosisJesús Rivera-Esteban, Angelo Armandi, Salvador Augustin, et al.
Metabolites|April 3, 2021
Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Metabolism: Clinical and Experimental|November 21, 2024
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillanceAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
BMJ (Clinical Research Ed.)|January 19, 2021
Management of non-alcoholic fatty liver diseaseMaria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
The American Journal of Gastroenterology|October 27, 2025
Reply to Yang et alNuria Perez-Diaz-Del-Campo, Zobair M Younossi, Elisabetta Bugianesi
Metabolism: Clinical and Experimental|September 6, 2016
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonistsStergios A Polyzos, Elisabetta Bugianesi, Jannis Kountouras, et al.
Journal of Gastroenterology and Hepatology|February 22, 2013
Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosisFederico Salomone, Giovanni Li Volti, Chiara Rosso, et al.
Nutrients|February 13, 2025
Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging TherapiesEleonora Dileo, Francesca Saba, Mirko Parasiliti-Caprino, et al.
Frontiers in Endocrinology|December 3, 2021
The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative ReviewAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Nature Reviews. Gastroenterology & Hepatology|January 4, 2026
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Pageof 33

Showing results (41-50 of 326) with videos related to

Sort By:
Pageof 33
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosisJesús Rivera-Esteban, Angelo Armandi, Salvador Augustin, et al.
Metabolites|April 3, 2021
Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Metabolism: Clinical and Experimental|November 21, 2024
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillanceAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
BMJ (Clinical Research Ed.)|January 19, 2021
Management of non-alcoholic fatty liver diseaseMaria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
The American Journal of Gastroenterology|October 27, 2025
Reply to Yang et alNuria Perez-Diaz-Del-Campo, Zobair M Younossi, Elisabetta Bugianesi
Metabolism: Clinical and Experimental|September 6, 2016
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonistsStergios A Polyzos, Elisabetta Bugianesi, Jannis Kountouras, et al.
Journal of Gastroenterology and Hepatology|February 22, 2013
Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosisFederico Salomone, Giovanni Li Volti, Chiara Rosso, et al.
Nutrients|February 13, 2025
Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging TherapiesEleonora Dileo, Francesca Saba, Mirko Parasiliti-Caprino, et al.
Frontiers in Endocrinology|December 3, 2021
The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative ReviewAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Nature Reviews. Gastroenterology & Hepatology|January 4, 2026
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Pageof 33